Literature DB >> 14985919

Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression.

David H Overstreet1, Joseph Hlavka, John P Feighner, Gabriela Nicolau, Jeffrey S Freed.   

Abstract

BACKGROUND: Nemifitide is a novel peptide analog of melanocyte-inhibiting factor (MIF) that has been reported to relieve depressive symptoms in a very short period.
OBJECTIVES: The Flinders Sensitive Line (FSL) rat, a genetic animal model of depression with innate exaggerated immobility in the forced swim test, was used to obtain more detailed information about the antidepressant-like effects of nemifitide.
METHODS: The FSL rats were treated chronically with various doses of nemifitide or reference antidepressants desipramine and fluoxetine for 5 or 14 days and the forced swim test was conducted 22-24 h after the last treatment.
RESULTS: Nemifitide significantly increased swimming in the FSL rats at both low (0.025-0.3 mg/kg) and high (3.0-15.0 mg/kg) doses but not at intermediate (0.4-2.4 mg/kg) doses. Nemifitide (0.3 mg/kg) and desipramine (5.0 mg/ kg) significantly increased swimming in the FSL rats after just 5 days of treatment, but fluoxetine (5.0 mg/kg) did not. Nemifitide (0.3 mg/kg) and fluoxetine (5.0 mg/kg) had long-lasting effects, but desipramine (5.0 mg/kg) did not.
CONCLUSIONS: These findings support the value of developing nemifitide and its analogs as potential antidepressants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985919     DOI: 10.1007/s00213-004-1815-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  Effects of MIF-1 and three related peptides on reserpine-induced hypothermia in mice.

Authors:  A J Kastin; L C Honour; D H Coy
Journal:  Pharmacol Biochem Behav       Date:  1981-12       Impact factor: 3.533

Review 2.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation.

Authors:  V Raghavendra; G Kaur; S K Kulkarni
Journal:  Eur Neuropsychopharmacol       Date:  2000-12       Impact factor: 4.600

Review 4.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

5.  Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant.

Authors:  John P Feighner; Gabriela Nicolau; Henry Abajian; Nadia Cardillo Marricco; John Morrison; Lev Sverdlov; Joseph Hlavka; George Tonelli; Carlo Di Spirito; George Faria
Journal:  Biopharm Drug Dispos       Date:  2002-01       Impact factor: 1.627

6.  Selective breeding for increased cholinergic function: development of a new animal model of depression.

Authors:  D H Overstreet
Journal:  Biol Psychiatry       Date:  1986-01       Impact factor: 13.382

7.  Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness.

Authors:  C D van der Velde
Journal:  Peptides       Date:  1983 May-Jun       Impact factor: 3.750

8.  Spatial working and reference memory in rats bred for autonomic sensitivity to cholinergic stimulation: acquisition, accuracy, speed, and effects of cholinergic drugs.

Authors:  P J Bushnell; E D Levin; D H Overstreet
Journal:  Neurobiol Learn Mem       Date:  1995-03       Impact factor: 2.877

9.  Increased REM sleep in rats selectively bred for cholinergic hyperactivity.

Authors:  P J Shiromani; D Overstreet; D Levy; C A Goodrich; S S Campbell; J C Gillin
Journal:  Neuropsychopharmacology       Date:  1988-05       Impact factor: 7.853

10.  The effect of tianeptine and sertraline in three animal models of depression.

Authors:  J P Kelly; B E Leonard
Journal:  Neuropharmacology       Date:  1994-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.